Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Purchases $33,725.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi bought 47,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average price of $0.71 per share, for a total transaction of $33,725.00. Following the completion of the acquisition, the chief executive officer now owns 1,214,775 shares in the company, valued at $862,490.25. This represents a 4.07 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Krishna Vaddi also recently made the following trade(s):

• On Monday, December 30th, Krishna Vaddi acquired 10,000 shares of Prelude Therapeutics stock. The shares were acquired at an average price of $1.20 per share, for a total transaction of $12,000.00.
• On Wednesday, December 18th, Krishna Vaddi bought 100,000 shares of Prelude Therapeutics stock. The shares were acquired at an average cost of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Trading Up 5.4 %

Shares of NASDAQ:PRLD opened at $0.74 on Monday. Prelude Therapeutics Incorporated has a 1-year low of $0.66 and a 1-year high of $6.80. The stock has a market cap of $41.08 million, a PE ratio of -0.42 and a beta of 1.43. The stock’s fifty day simple moving average is $0.97 and its two-hundred day simple moving average is $1.58.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.11. The firm had revenue of $4.00 million for the quarter. On average, sell-side analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prelude Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Prelude Therapeutics during the third quarter worth $100,000. State Street Corp raised its stake in shares of Prelude Therapeutics by 35.1% during the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock worth $592,000 after purchasing an additional 74,300 shares during the period. Barclays PLC boosted its holdings in shares of Prelude Therapeutics by 86.0% in the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after buying an additional 12,564 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Prelude Therapeutics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock worth $811,000 after buying an additional 29,765 shares during the last quarter. Finally, Walleye Capital LLC grew its position in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after buying an additional 67,946 shares during the period. Hedge funds and other institutional investors own 79.72% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.